CJC-1295 with DAC
2 mg
Drug Affinity Complex Modified GRF
CJC-1295 with DAC
Long-acting GHRH analogue for sustained GH elevation research.
Prices in AUD. Tax included.
Research Use Only: FOR LABORATORY RESEARCH USE ONLY. Not for human consumption, injection, or therapeutic use. All products are sold strictly as research chemicals. By purchasing, you confirm you are 18+ and agree to use products solely for legitimate research purposes.
Description
CJC-1295 with DAC (Drug Affinity Complex) is a modified growth hormone-releasing hormone analogue with an extended half-life due to its DAC modification, which enables covalent binding to serum albumin. This results in sustained GH elevation over days rather than hours, making it suitable for long-duration research protocols.
Specifications
- SKU
- CJCDAC-2MG
- Size
- 2 mg
- Form
- Lyophilised Powder
- Purity
- >99%
- Storage
- -20°C (lyophilised), 2-8°C (reconstituted)
- Shipping
- Australia Post — 3–5 business days
Research Summary
The DAC modification extends the half-life to approximately 6-8 days, compared to 30 minutes for native GHRH. Studies show sustained elevation of GH and IGF-1 levels with less frequent administration. Research indicates a more tonic (rather than pulsatile) GH release pattern compared to non-DAC variants.
Testing Protocol
- HPLC Purity Analysis
- Mass Spectrometry Identity Verification
- Endotoxin Screening (LAL Test)